Paxmedica enters research collaboration agreement with polomar health for phase ii study in autism spectrum disorder

Collaboration will investigate a next generation orally delivered anti-purinergic compound proof-of-concept study based on one of paxmedica's proprietary pipeline candidates tarrytown, ny, june 08, 2023 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd) and other serious conditions with intractable neurologic symptoms, today announced that it has entered into an agreement with polomar health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder. emodin is an orally bioavailable selective p2x7 inhibitor, and is currently available as a component in a number of over-the-counter nutritional supplements.
PXMD Ratings Summary
PXMD Quant Ranking